Molecular Mycobacteriology, Research Center Borstel, Borstel, Germany.
Antimicrob Agents Chemother. 2012 May;56(5):2743-5. doi: 10.1128/AAC.06227-11. Epub 2012 Feb 27.
The ribosomal L3 protein was identified as a novel target in linezolid (LZD)-resistant Mycobacterium tuberculosis strains. Next-generation sequencing confirmed rplC T460C as the sole mutation in an LZD-resistant M. tuberculosis H37Rv strain selected in vitro. Sequencing analysis revealed the rplC T460C mutation in eight further LZD-resistant isolates (three in vitro-selected mutants and five patient isolates, including isolates from three different patients that developed LZD resistance during treatment) but in none of the susceptible control strains (n = 84).
核糖体 L3 蛋白被鉴定为利奈唑胺（LZD）耐药结核分枝杆菌菌株的一个新的作用靶点。下一代测序技术证实 rplC T460C 是体外筛选的一株 LZD 耐药结核分枝杆菌 H37Rv 株中唯一的突变。测序分析显示，在其他 8 株 LZD 耐药分离株（3 株体外筛选的突变株和 5 株患者分离株，包括 3 位在治疗过程中发生 LZD 耐药的不同患者的分离株）中存在 rplC T460C 突变，但在 84 株敏感对照株中均未发现该突变。
